Alnylam Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
Alnylam Pharmaceuticals stock last closed at $331.91, up 0.65% from the previous day, and has increased 33.47% in one year. It has overperformed other stocks in the Biotechnology industry by 1.04 percentage points. Alnylam Pharmaceuticals stock is currently +61.22% from its 52-week low of $205.87, and -0.54% from its 52-week high of $333.70.
As of Jul 3, 2025, there are 130.39M ALNY shares outstanding. The market cap of ALNY is $43.28B. In the last 24 hours, 431,000 ALNY shares were traded.
How to Buy Alnylam Pharmaceuticals Stock
Wondering how to invest in Alnylam Pharmaceuticals stock? Here's how.
Decide where to buy Alnylam Pharmaceuticals stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you decide where to buy Alnylam Pharmaceuticals stock.
Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
Deposit money your brokerage account: Choose your method of payment and add your info.
Evaluate Alnylam Pharmaceuticals stock: The Alnylam Pharmaceuticals ticker symbol is ALNY. Is Alnylam Pharmaceuticals stock a good investment? Should you buy shares of ALNY? How do ALNY's underlying business fundamentals look? Do top analysts think Alnylam Pharmaceuticals is a good buy? Why has ALNY's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if ALNY is a good stock to buy).
Execute your ALNY purchase: Decide if you will purchase ALNY shares at the current market price or use a limit order to purchase ALNY shares at a particular price.
Keep tabs on your ALNY investment: Create a watchlist to get the latest news on your new investment in Alnylam Pharmaceuticals shares.
Step 1: Decide where to buy Alnylam Pharmaceuticals stock
You will need an online brokerage account in order to access the NASDAQ market and buy ALNY stock.
A brokerage account is an investment account that allows you to buy and sell a number of financial instruments, such as stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
In our opinion, eToro is the best brokerage. eToro gives you:
Invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
Access to global financial markets: From Tech to Industrials, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by opening an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for a brokerage account
Now that you've chosen the best brokerage, the next step is to fill out some personal info so you can invest in ALNY today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Alnylam Pharmaceuticals stock
Once you have selected the best place to buy Alnylam Pharmaceuticals stock, it's crucial to analyze their stock prior to investing, so you can comprehend the risk as well as the upside.
Alnylam Pharmaceuticals shares data
ALNY Price
$331.91
1w %
4.29%
1y %
33.47%
5y %
117.75%
P/E
-158.81x
P/B
374.91x
P/S
18.33x
PEG
N/A
Revenue
$2.35B
Earnings
-$269.70M
Fore. Rev. Growth
28.33%
Fore. Earn. Growth
N/A
Market Cap
$43.28B
Next Earnings
Jul 30, 2025
Next Dividend
N/A
Fundamentals of ALNY
WallStreetZen was designed to help part-time investors perform more in-depth fundamental analysis quickly.
ALNY has cash burn of 75385000. It has enough cash and short-term investments to cover this for at least one year.
There are more short-term assets than short-term liabilities on the ALNY balance sheet.
There are more short-term assets than long-term liabilities on the ALNY balance sheet.
ALNY profit margin has gone up from -16.6% to -11.5% in the past year.
ALNY has $2.63B in cash and short term investments. This is enough to cover its annual cash burn of $75.39M.
Failed Financial Due Diligence Checks:
Total ALNY debt is higher than 5 years ago, relative to shareholder equity.
ALNY has a relatively high debt to equity ratio of 35.5.
Do Wall Street analysts think it's a good time to buy Alnylam Pharmaceuticals stock
Out of 16 Wall Street analysts who give ratings on ALNY, the consensus analyst rating on ALNY is a Strong Buy
It's important to note that analyst forecasts are not recommendations, nor are they financial advice.
Most Recent ALNY Analyst Recommendations
Keay Nakae, a top 15% analyst from Chardan Capital maintains ALNY with a strong buy rating and raises their ALNY price target from $300.00 to $325.00, on May 2, 2025.
Michael Ulz, a top 11% analyst from Morgan Stanley maintains ALNY with a hold rating and lowers their ALNY price target from $284.00 to $268.00, on Apr 11, 2025.
Patrick Trucchio, a top 26% analyst from HC Wainwright & Co. reiterates ALNY with a buy rating and maintains their ALNY price target from $500.00 to $500.00, on Apr 2, 2025.
Greg Harrison, a top 28% analyst from ScotiaBank maintains ALNY with a buy rating and raises their ALNY price target from $338.00 to $342.00, on Mar 31, 2025.
Joshua Smith, a top 49% analyst from Redburn Atlantic initiates coverage on ALNY with a strong buy rating and announces their ALNY price target of $353.00, on Mar 31, 2025.
Last year, ALNY revenue was $2.35B. Over the last 5 year, ALNY's revenue has increased by 52.37% per year. This was faster than the Biotechnology industry average of 42.03%.
In the last year, insiders at ALNY have sold more shares than they have bought.
Yvonne Greenstreet, Chief Executive Officer of ALNY, was the latest ALNY insider to buy. They bought $1,439,090.40 worth of ALNY shares on Jun 2, 2025.
No, Alnylam Pharmaceuticals doesn't provide an income stream by paying out dividends.
What others are saying about ALNY
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your ALNY purchase
You have two main order types:
Market order: A market order is an order to buy or sell a security at the best available price. Market orders are usually sufficient.
Limit order: A limit order lets you buy or sell a stock at a specific price (or better). If you want to be sure you're buying or selling at an exact dollar amount, use a limit order.
Press the Open Trade button and your broker will execute the order.
If you want additional assistance investing in stocks on eToro, watch the how to video below:
How much does it cost to buy one Alnylam Pharmaceuticals share?
As of Jul 3, 2025, it costs $331.91 to buy one share of Alnylam Pharmaceuticals stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $100, you can buy 0.301 shares of ALNY.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.